Physician profile
Daniel H Chang
NPI 1184618266
$820,127.41
in general payments reported to CMS, 2019-2025
26 companies · $89K in 2025
The $89K reported for 2025 was more than what 99% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $106K · 2020: $155K · 2021: $147K · 2022: $150K · 2023: $109K · 2024: $64K · 2025: $89K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $252K · Travel and Lodging: $4,624 · Food and Beverage: $4,178 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $263 · Education: $100.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $252,458.92 |
| Travel and Lodging | $4,624.21 |
| Food and Beverage | $4,177.76 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $262.50 |
| Education | $100.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $593,482.23 | 2019-2025 | Intralase Fs Femtosec Laser, Compact Intuitiv, Ifs Advanced Femtosec Laser |
| Allergan, INC. | $80,387.33 | 2019-2022 | |
| Carl Zeiss Meditec, INC. | $53,518.16 | 2019-2025 | Iolmaster 700, Visumax, Mel 90 |
| Beaver-Visitec International, INC. | $53,400.00 | 2025 | |
| Abbvie INC. | $35,389.94 | 2022-2025 | Vuity |
| Tarsus Pharmaceuticals, INC. | $2,239.34 | 2025 | |
| Carl Zeiss Meditec USA, INC. | $453.22 | 2023-2025 | Iolmaster 700, Quatera 700 |
| Johnson & Johnson Vision Care, INC. | $312.80 | 2022-2025 | Tecnis Iol, Acuvue, Veritas Vision System |
| Dompe US, INC. | $169.42 | 2023-2024 | Oxervate |
| New World Medical,INC. | $112.97 | 2022 | |
| Integra Lifesciences Corporation | $96.83 | 2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $90.92 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $75.35 | 2023 | Veritas Vision System, Tecnis Iol |
| Eyevance Pharmaceuticals LLC | $67.07 | 2020-2021 | |
| Sun Pharmaceutical Industries INC. | $50.09 | 2020-2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mentor Worldwide LLC | $44.75 | 2025 | Mentor Memorygel Resterilizable Gel Sizer |
| Kala Pharmaceuticals, INC. | $39.58 | 2019-2021 | |
| Genzyme Corporation | $32.06 | 2023 | |
| Glaukos Corporation | $31.43 | 2025 | Idosetr, Istent Infinite |
| Harrow Eye, LLC | $27.76 | 2025 | Vevye |
| Alcon Vision LLC | $25.69 | 2025 | |
| Oyster Point Pharma, INC. | $25.56 | 2023 | Tyrvaya |
| Bausch & Lomb Americas INC. | $22.68 | 2023 | Xiidra |
| Amgen INC. | $16.17 | 2024 | Tepezza |
| Galderma Laboratories, L.P. | $16.06 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Chang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.